A Randomized, Double-Blind, Placebo-Controlled, SingleAscending Dose Study to Assess the Safety, Tolerability,and Pharmacokinetics of C2N-8E12 in Subjects withProgressive Supranuclear Palsy

Investigator: Adam Boxer, MD, PhD

Location(s): United States


This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).